The QualityStocks Daily Tuesday, July 14th, 2020

Today's Top 3 Investment Newsletters

MarketClub Analysis (PRCP) +111.73%

StocksToBuyNow (INMB) +77.97%

QualityStocks (VBIO) +57.79%

The QualityStocks Daily Stock List

Aqua Metals, Inc. (AQMS)

Wall Street Reporter, Zacks, Market Chameleon, The Fly, State Reviewer, Investors Observer, Proactive Investors, Market Screener, Finviz, Stocktwits, YCharts, Simply Wall St, Stockhouse, last10k, GuruFocus, CSI Market, Invest Million, FX Empire, Street Insider, Invest Chronicle, InvestorsHub, TMXmoney, Nasdaq, Insider Tracking, Equities.com, Business Wire, ETF.com, Stocknews, GlobeNewswire, Simply Wall St, Seeking Alpha, MacroTrends, Morningstar, and Directors Talk Interviews reported earlier on Aqua Metals, Inc. (AQMS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aqua Metals, Inc. is reinventing lead recycling with its AquaRefining™ technology. AquaRefining (unlike smelting) is a room temperature, water-based process that emits less pollution. The Company’s mission is to increase worldwide lead production without increasing emissions. Its pioneering technology, AquaRefining, delivers ultrapure lead at a high yield while lessening environmental footprint and permitting. Established in 2014, Aqua Metals has its corporate headquarters in McCarran, Nevada. The Company’s shares trade on the NasdaqCM.

The intention of Aqua Metals’ modular systems are to allow the Company to significantly lessen environmental impact and scale lead acid battery recycling production capacity through licensing the AquaRefining technology to partners. The Company states that this could help to meet increasing demand for lead to power new applications. This includes stop/start automobile batteries that complement the vehicle’s main battery, lead acid batteries that are in electric vehicles, Internet data centers, alternative energy applications including solar, wind, and grid scale storage.

AquaRefinings’ modular design can be implemented in stand-alone facilities. In addition, it can be licensed to partners for placement at existing battery recycling facilities.

AquaRefining utilizes a room temperature, closed-loop, water-based process combined with non-toxic, biodegradable organic elements to produce 99.99 percent pure lead. This is equal to or better than mining. There is no need for secondary processing. AquaRefining uses electroplating with continuous removal of lead enabling one module to produce approximately 2.5-3 tonnes of ultra pure lead per day.

In June, Aqua Metals announced it successfully performed a test run of the first electrolyzer as part of its V1.25L program. This program comprises three iterations classified as V1.25a, V1.25b, and the final iteration, V1.25L, the latter of which will be used to create the licensing ready AquaRefining electrolyzer package for Aqua Metals’ equipment supply and licensing offerings.

The Company states that the V1.25L program does not fundamentally change the important operating parameters of the AquaRefining electrolyzers. The design of the program is to build upon previous operational success and target key areas of “case hardening,” therefore providing a strong and robust AquaRefining equipment value proposition to the market.

Aqua Metals, Inc. (AQMS), closed Tuesday's trading session at $1.12, up 2.7523%, on 295,294 volume with 625 trades. The average volume for the last 3 months is 559,576 and the stock's 52-week low/high is $0.330000013/$2.1400001.

chart

Fortress Biotech, Inc. (FBIO)

Zacks, GuruFocus, TMXmoney, Stocktwits, Streetwise Reports, Morningstar, GlobeNewswire, Simply Wall St, YCharts, Invest Chronicle, Stockwatch, Stock News, BioPharmCatalyst, Infront Analytics, MacroTrends, Investing.com, ETF.com, Equities.com, Seeking Alpha, Street Insider, Stockhouse, Preferred Stock Channel, Market Chameleon, Nasdaq, Stockopedia, Barchart, and Market Screener reported earlier on Fortress Biotech, Inc. (FBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Fortress Biotech, Inc. is a biopharmaceutical company centered on acquiring, developing, and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates. The Company has five marketed prescription pharmaceutical products and greater than 25 programs in development at Fortress, at its majority-owned and majority-controlled partners, and at partners it founded and in which it holds considerable minority ownership positions. Product candidates encompass six large-market areas, including oncology, rare diseases, and gene therapy that enable Fortress to create value while lessening risk for shareholders.

The Company formerly went by the name Coronado Biosciences, Inc. It changed its name to Fortress Biotech, Inc. in April of 2015. Founded in 2006, Fortress Biotech is headquartered in New York City and lists on the NasdaqGS.

Fortress Biotech has established partnerships with some of the globe’s top academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential. These include partnerships with Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and Nationwide Children’s Hospital.

Fortress Biotech leverages its extensive biopharmaceutical business and comprehensive drug development expertise to build a pipeline of commercial-stage products and development-stage product candidates, and to advance its products and pipeline as efficiently as possible with its partners. Its current portfolio includes 5 revenue-generating dermatology products.

Last month, Fortress Biotech announced the publication of a study, “Estimated birth prevalence of Menkes disease and ATP7A-related disorders based on the Genome Aggregation Database (gnomAD),” in Molecular Genetics and Metabolism Reports. The study was published online in June of 2020. It will be published in the print edition of the journal in September 2020. Fortress Biotech was recently ranked number 10 in Deloitte’s 2019 Technology Fast 500™. This is an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences, and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period. Recently, Fortress Biotech announced that it was added to the Russell 3000® index following Russell’s annual reconstitution of its U.S. and global equity indexes.

Fortress Biotech, Inc. (FBIO), closed Tuesday's trading session at $2.70, up 3.0534%, on 513,271 volume with 3,790 trades. The average volume for the last 3 months is 770,376 and the stock's 52-week low/high is $1.03999996/$3.20000004.

chart
n

Kindred Biosciences, Inc. (KIN)

NetworkNewsWire, StreetWise Reports, Marketing Sentinel, Zacks, Stockhouse, MacroTrends, Simply Wall St, Ceo.ca, Proactive Investors, EarningsCast, Stocktwits, Equity Clock, last10k, Equities.com, Morningstar, Finviz, Market Screener, Wallet Investor, TMXmoney, Stocknews, YCharts, Seeking Alpha, Nasdaq, GuruFocus, InvestorsHub, and FX Empire reported earlier on Kindred Biosciences, Inc. (KIN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Kindred Biosciences, Inc. concentrates on saving and improving the lives of pets. Its mission is to bring unique biologics to veterinary medicine. The Company’s core strategy is to identify targets that have already been proven safe and effective in humans. Its expertise is in the development of biologics: monoclonal antibodies and recombinant proteins. Kindred Biosciences has a deep pipeline of novel biologics in development across numerous therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and an extensive intellectual property (IP) portfolio. The Company lists on the NasdaqGS and is headquartered in Burlingame, California.

Kindred Biosciences has inventive biologics in development specifically for dogs, their owners, and the veterinarians that care for them. The Company is taking a multi-pronged approach toward atopic dermatitis. This the leading reason owners take their dog to the veterinarian. Kindred is also developing product candidates to address parvovirus and inflammatory bowel disease in dogs.

In addition, Kindred Biosciences is a front runner in developing unique new treatments in feline medicine. The Company’s feline pipeline includes “Non-regenerative Anemia in Cats-KIND-510a”. Anemia has been associated with progression in feline chronic kidney disease, and potentially contributes to renal hypoxia, as well as decreased energy and appetite (Jessica Quimby, DVM, Ph.D., DACVIM).

This past May, Kindred Biosciences announced it entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine candidate for COVID-19. With this agreement, Kindred will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame. There, the Company will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices. It will provide it to Vaxart to be formulated into a vaccine tablet to be taken by mouth instead of by needle injection. Kindred Biosciences will manufacture the vaccine for clinical trials starting in the second half of this year.

Kindred Biosciences, Inc. (KIN), closed Tuesday's trading session at $4.11, up 6.7532%, on 204,922 volume with 1,761 trades. The average volume for the last 3 months is 421,342 and the stock's 52-week low/high is $3.10500001/$11.9300003.

chart

Orchid Ventures, Inc. (ORVRF)

Daily Stock Deals, Stock Day Media, Technical420, Morningstar, Canadian Insider, Investing.com, Stockhouse, Seeking Alpha, Accesswire, FX Empire, Nasdaq, Central Charts, InvestorX, Market Screener, TipRanks, Wallet Investor, InvestorsHub, Top Shelf News, GuruFocus, Investing News, Dividend Investor, Stockwatch, and Barchart reported earlier on Orchid Ventures, Inc. (ORVRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Orchid Ventures, Inc. is a multi-state cannabis innovation company listed on the OTC Markets. Orchid Essentials is an award-winning cannabis brand with THC (tetrahydrocannabinol) and CBD (cannabidiol) product lines presently selling in 250-plus dispensaries across California and Oregon. Orchid has plans to expand its brand into new markets such as Nevada, New York, Puerto Rico, Canada, and other international markets. Orchid Ventures has its corporate headquarters in Irvine, California.

The Company's Management Team brings substantial branding, product development, and distribution experience. This Team has a proven record of accomplishment of scaling businesses and building sustainable revenue growth via value-generating partnerships and innovation that creates enterprise value.

The Company launched in the States of Oregon and California in August of 2017. It has since developed a mass-market brand and loyal consumer following with its premium cannabis products and inventive vape hardware delivery system.

Orchid Ventures has diversified its portfolio to include PurTec Delivery Systems. PurTec is a company that produces, markets, and sells clean vaporizer hardware that has been emissions tested against the most stringent standards globally set forth by the European Union (EU).

Orchid Ventures, through its wholly owned subsidiary, has launched a patented and clinically proven bioavailability solution to increase the absorption of THC and other cannabinoids. This makes products considerably more effective and an activation time of less than five minutes.

Last month, Orchid Ventures announced it has partnered with Driven (OTCQB:DRVD) to launch Orchid on their new ecommerce platform, Brand Budee. Driven is California's fastest growing online cannabis retailer and direct-to-consumer logistics company. Its new ecommerce platform Brand Budee, enables Orchid customers to buy directly from the Orchid website for delivery throughout California.

Mr. Corey Mangold, Founder & Chief Executive Officer of Orchid Ventures, said, "We are excited to be partnering with Driven on the new Brand Budee platform. We have already integrated it into our website and customers are now able to purchase products for delivery throughout the largest cannabis market in the country. Driven's other delivery service, GanjaRunner, has been one of Orchid's larger retail accounts for over a year and lately we have seen a significant increase in sales through their platform."

Orchid Ventures, Inc. (ORVRF), closed Tuesday's trading session at $0.0417, even for the day, on 10 volume with 1 trade. The average volume for the last 3 months is 56,237 and the stock's 52-week low/high is $0.000099999/$0.239999994.

chart

Quarterhill, Inc. (QTRHF)

TradingView, RocketNews, Zacks, PR Newswire, Investors Hangout, Wallet Investor, SmarterAnalyst, EquityMood, OTC Markets, Stockhouse, Stocktwits, GuruFocus, MarketBeat, Business Insider, MarketWatch, Seeking Alpha, Market Screener, Stockwatch, Morningstar, Barchart, Dividend Investor, Dividend.com, InvestorsHub, IT News Online, and MacroTrends reported previously on Quarterhill, Inc. (QTRHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A diversified holding company, Quarterhill, Inc. focuses on the acquisition, management, and growth of companies in dedicated technology areas. This includes vertical market software and solutions, intelligent industrial systems, and innovation and licensing. The Company formerly went by the name Wi-LAN, Inc. It changed its corporate name to Quarterhill, Inc. in June of 2017. The OTCQX-listed Company is headquartered in Kitchener, Ontario.

IRD (International Road Dynamics) is a wholly-owned subsidiary of Quarterhill. IRD is a multi-discipline, technology company and a top provider of Intelligent Transportation Systems (ITS). IRD’s expertise is integrating ITS technologies into systems designed to solve unique and challenging transportation problems. Furthermore, VIZIYA is a wholly-owned subsidiary of Quarterhill. VIZIYA is a software and services provider that helps companies optimize their asset performance.

Wi-LAN is a wholly-owned subsidiary of Quarterhill. It focuses on patent licensing. WiLAN develops and commercializes innovative patented technologies, manages intellectual property (IP), and licenses these inventions to corporations.

Quarterhill's emphasis is on seeking out acquisition opportunities at reasonable valuations, which provide a foundation for recurring revenues, predictable cash flows and margins, profitable growth, intimate customer relationships, and dedicated management teams. Mergers and Acquisitions (M&A) are an important element of its growth strategy. Quarterhill will look for organic growth in its existing businesses and once acquired, it will also look at tuck-in acquisitions that can be part of those same businesses providing incremental revenue and professional growth opportunities.

Last month, Wi-LAN provided an update on its continuing litigation with Apple, Inc. Following a jury verdict win on January 24, 2020 of $85.23 million in a damages-only re-trial in the United States District Court for the Southern District of California, the Court ruled in June on all post-trial motions and entered final judgment in favor of WiLAN, maintaining the full jury verdict and denying Apple's motions for retrial or lowering the damages award.

Additionally, the Court awarded WiLAN an additional amount of $23.75 million in pre-judgment interest. The total award in the Final Judgment is $108.98 million. Moreover, WiLAN is entitled to post-judgment interest from June 16, 2020 until the date this Final Judgment is satisfied.

Quarterhill, Inc. (QTRHF), closed Tuesday's trading session at $1.47, up 0.961538%, on 12,799 volume with 25 trades. The average volume for the last 3 months is 34,714 and the stock's 52-week low/high is $0.295049995/$1.68910002.

chart

ReShape Lifesciences, Inc. (RSLS)

Street Insider, AI Stock Finder, 4-Traders, Stockopedia, Accesswire, YCharts, Simply Wall St, InvestorsHub, GuruFocus, Market Screener, Stockwatch, Insider Financial, TMXmoney, Seeking Alpha, Investing.com, Nasdaq, Barchart, ETF.com, PR Newswire, and Morningstar reported earlier on ReShape Lifesciences, Inc. (RSLS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ReShape Lifesciences, Inc. is a foremost developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases. Its current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape Vest™, an investigational device, to help treat more patients with obesity. The Company previously went by the name EnteroMedics, Inc. It changed its name to ReShape Lifesciences, Inc. in October of 2017. Established in 2002, the Company has its head office in San Clemente, California.

The design of the Food and Drug Administration (FDA)-approved LAP-BAND® Adjustable Gastric Banding System is to provide minimally invasive long-term treatment of severe obesity. It is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The LAP-BAND® procedure helps to decrease the amount of food consumed at one time. The design of LAP-BAND® is to help one lose excess weight at a gradual and healthy pace. The LAP-BAND® can be adjusted to meet one’s personal needs and weight loss objectives.

The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device. It wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShape Vest™ System is intended to enable quick weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

This past March, ReShape Lifesciences reported financial results for the three months and full year ended December 31, 2019. The Company recognized Revenue of $4.1 million in Q4 of 2019 and $15.1 million for the full year 2019. It grew full year 2019 U.S. Lap-Band sales and reversed years of declining Revenues.

ReShape Lifesciences expanded Lap-Band System presence via new digital media launches and private presentations of long-term safety and efficacy data at key global surgical conferences. The Company completed the transition of global Lap-Band System sales to ReShape and established key distributor relationships. Moreover, it continued enrollment of patients for the Endure clinical study of the ReShape Gastric Vest in Europe.

ReShape Lifesciences, Inc. (RSLS), closed Tuesday's trading session at $3.00, off by 4.7619%, on 1,618 volume with 7 trades. The average volume for the last 3 months is 761 and the stock's 52-week low/high is $2.75999999/$14.25.

chart

ScoutCam, Inc. (SCTC)

Wolf Street, Validea, Stock Market Watch, Stockhouse, Stockopedia, Invezz.com, Seeking Alpha, InvestorsHub, TradingView, Barchart, VentureLine, Morningstar, Nasdaq, Simply Wall St, GlobeNewswire, and OTC Markets reported previously on ScoutCam, Inc. (SCTC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

ScoutCam, Inc. specializes in developing minimally invasive endosurgical tools and highly innovative imaging solutions. It designs and manufactures endoscopy devices and micro medical camera systems. The Company has developed a range of micro CMOS (Complementary Metal-Oxide Semiconductor) video cameras. This includes micro ScoutCam™ 1.2, which to the best of the Company’s knowledge, is the smallest in the world. ScoutCam devices have been used across the medical, aerospace, industrial, and research and defense industries. ScoutCam is based in Omer, Israel.

ScoutCam Ltd. is a fully-owned private subsidiary of Medigus Ltd. Medigus is a public company traded on NASDAQ and TASE (Tel Aviv Stock Exchange) (ticker: MDGS). Medigus is a technology company developing minimally invasive tools and it is an innovator in direct visualization technology. ScoutCam Ltd. is the wholly-owned subsidiary of ScoutCam, Inc.

ScoutCam (based on its proprietary technology) designs and manufactures endoscopy and micro camera systems for partner companies. These include major players in the medical and industrial fields. The innovative cameras are suitable for industrial and medical applications.

micro ScoutCam™, the medical camera series, offers 1.2mm – 6.5mm diameter micro-cameras. It features a micro medical camera equipped with micro CMOS sensors and ultimate image technology, which cover a wide spectrum of inventive medical applications. It is already used as a medical inspection camera for fiber optic endoscopes, as an endoscopy camera, gastroscopy camera, laparoscopy camera, urology camera, arthroscopy camera, gynecology camera, surgical camera, ent camera, and more.

ScoutCam’s high resolution technology has unique properties that have been authenticated by customers, such as NASA, in the strictest environmental conditions. This includes extreme temperatures, vibrations, and radiation. ScoutCam 8.0 HD was chosen by NASA to be incorporated into NASA’s Visual Inspection Poseable Invertebrate Robot 2 (VIPIR2). VIPIR2 is a robotic, multi-capability inspection tool. It is being used as part of NASA’s Robotic Refueling Mission 3 (RRM3). It was launched into space in December of 2018.

This past May, ScoutCam announced a breakthrough with the successful integration of its wireless micro ScoutCam into medical endoscope devices, formally introducing the healthcare industry’s first operating room-ready wireless endoscope, to ScoutCam’s knowledge. The device has been cleared for marketing by the U.S. Food and Drug Administration (FDA) and meets the Federal Communications Commission requirements. The device was developed for a privately held orthopedic company.

In June, ScoutCam announced the approval of its endoscope irrigation patent in Canada. The patented technology has already been approved for patents in other jurisdictions, including the USA, the European Union (EU), and Japan. The patented technology showcases the resistance and durability of the Company’s micro-cameras and the ScoutCam's ability to decrease the diameter of its devices versus competing endoscopes/borescopes with traditional irrigation technology, further positioning ScoutCam as a leader in the medical, industrial, as well as aeronautic/defense sectors.

ScoutCam, Inc. (SCTC), closed Tuesday's trading session at $0.9886, even for the day, on 4,100 volume. The average volume for the last 3 months is 2,255 and the stock's 52-week low/high is $0.602199971/$3.00.

chart

North American Cannabis Holdings, Inc. (USMJ)

Wolf Street, Pink Investing, PotStockNews, Micro Small Cap, hot Stocked, PR Newswire, Simply Wall St, Dividend Investor, Real Investment Advice, Tech Stock Observer, Pitchbook, GuruFocus, Research Pool, Nasdaq, Stockhouse, Emerging Growth, SmallCap Exclusive, Investor Ideas, Morningstar, Market Exclusive, Daily Marijuana Observer, P&T Community, Insider Financial, Seeking Alpha, BioSpace, Wallet Investor, InvestorsHub, Accesswire, Infront Analytics, and GlobeNewswire reported on North American Cannabis Holdings, Inc. (USMJ), and today we report on the Company, here at the QualityStocks Daily Newsletter.

North American Cannabis Holdings, Inc., by way of its subsidiaries, operates in the legal cannabis market in the United States. The Company conducts various pilots in the legal cannabis sector so as to explore different high growth potential business opportunities. The Company formerly went by the name Algae International Group, Inc. It changed its name to North American Cannabis Holdings, Inc. in June of 2015. North American Cannabis Holdings is based in Texas.

The Company also operates a destination beverage company. It enables consumers to interface with staff to learn about the specific benefits of cannabis, and select healthy and refreshing cannabis infused beverages. These beverages include custom blended hemp infused coffee, cold pressed juices, as well as smoothies. In addition, North American Cannabis offers raw hemp seeds and other hemp infused foods.

North American Cannabis has a curated product line of legal cannabinoids and accessories. All of its products are lab-tested and contain no THC (tetrahydrocannabinol) through a carefully monitored extraction process. The Company’s products are all natural, all safe, and all CBD (cannabidiol). North American Cannabis carries many CBD and CBG Smokable products in Pre Roll and Flower. It has more than 150 CBD, Hemp, and Cannabis Essentials products available online.

North American Cannabis’ eCommerce site is www.USMJ.com. USMJ is a subsidiary company of North American Cannabis Holdings. USMJ partners with premier CBD producers. USMJ curates each product selection to work as promised and to ensure each item it sells is safe and effective.

Recently, North American Cannabis Holdings said that because of overwhelming demand, USMJ.com has streamlined its process to becoming a Vendor on USMJ.com. The USMJ.com Vendor program launched some time ago. However, the Company said it has been a slowly growing process. Now, CBD/CBG Manufacturers and Vendors can apply and list their products on USMJ.com.

North American Cannabis Holdings, Inc. (USMJ), closed Tuesday's trading session at $0.0001, even for the day, on 13,516,794 volume with 67 trades. The average volume for the last 3 months is 22,853,017 and the stock's 52-week low/high is $0.000099999/$0.0005.

chart

AMP Limited (AMLTF)

Stock Scores, TeleTrader, TipRanks, Invest Tribune, PR Newswire, Dividend Investor, 4-Traders, Market Screener, Investing.com, Stockhouse, Morningstar, Stockwatch, TradingView, ad Wallet Investor reported previously on AMP Limited (AMLTF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

AMP Limited operates as a wealth management company in Australia and globally. It operates by way of the Australian Wealth Management, AMP Capital, AMP Bank, and New Zealand Wealth Management segments. AMP offers solutions and services across financial advice, investment management, banking, superannuation, self-managed superannuation funds (SMSFs), life insurance, retirement income and investing.

The Company lists on the OTC Markets. AMP Limited has its corporate headquarters in Sydney, Australia. The Company began in 1849 as the Australian Mutual Provident Society, offering life insurance. AMP has developed over 170 years to be a publicly listed, international wealth manager. AMP’s reach now spans around the world, where the Company uses its expertise to advise clients and customers in Asia, the Middle East, Europe, the United Kingdom (UK) and North America.

In 2009, AMP and China Life Group formed a strategic partnership. In 2011, AMP and AXA Asia Pacific merged and AMP and Mitsubishi UFJ Trust and Banking formed a strategic partnership. In 2017, AMP Capital takes a minority stake in U.S. based real estate investment manager PCCP.

Australian Wealth Management help its customers to save for, and to live well in retirement, with its retail and workplace superannuation products, self-managed superannuation funds services, and retirement income solutions and investments for individuals. AMP Bank provides customers with residential and investment property home loans, deposit and transaction accounts and SMSF products. AMP Bank also provides loans to AMP-aligned financial advice practices.

AMP Capital manages investments in equities, fixed income, diversified, multi-manager and multi-asset funds on behalf of clients worldwide. In 2018, AMP Capital managed real estate and infrastructure assets including shopping centers, airports, trains and pipelines, with $20.3 billion in infrastructure investments managed on behalf of funds and clients. New Zealand Wealth Management provides customers in New Zealand with financial products and services, directly and through one of the largest networks of financial advisers in the country.

Recently, AMP announced an agreement to sell its Australian and New Zealand wealth protection and mature businesses to Resolution Life, with a completion date in the first half of 2020.

AMP Limited (AMLTF), closed Tuesday's trading session at $1.28, up 56.0976%, on 500 volume. The average volume for the last 3 months is 822 and the stock's 52-week low/high is $0.620000004/$1.36000001.

chart

Dragon Jade International Limited (DGJI)

Awesome Penny Stocks, Zacks, Street Insider, Otc.Watch, last10k, Infront Analytics, Investors Hangout, Dividend Investor, Capital Cube, Trading View, Stockhouse, and Wallet Investor reported previously on Dragon Jade International Limited (DGJI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Dragon Jade International Limited concentrates on identifying, developing and marketing the next generation of herbal and natural products that improve people’s lives. The Company has significant expertise in human biological knowledge and marketing. Dragon Jade works to uncover the unique combination use of Traditional Chinese Medicine and Modern Western Medicine in treatment. The primary activity of the Company is investment holding. OTCQX-listed, Dragon Jade is headquartered in Hong Kong.

A provider of premier products and services, the Company serves high net worth and affluent middle class consumers in Greater China. Via its considerable worldwide experience and regional network, Dragon Jade focuses on identifying, developing, and marketing products from other countries to meet the growing demand for better health and quality of life in Asia.

Dragon Jade has organized a professional advisory panel comprising experts from the fields of medical, accounting and finance, legal, marketing research, and more. The advisory panel is responsible for the assessment and value appraisal of new Traditional Chinese Medicine and biotechnology projects.

Fundamentally, Dragon Jade is a medical group dedicated to developing and distributing medical and health products. As such, it has established a Medical Advisory Board to offer advice on the screening of potential medical projects and the exploration of new medical products aiming to enhance the quality of medical services in the community. The Company is working to develop and distribute a greater assortment of herbal and natural nutritional products that are more effective and safer.

Asia is the fastest growing region in sales and development of herbal and natural nutritional products. Therefore, Dragon Jade will develop the markets of developed countries and regions in Asia including Japan, Korea, Hong Kong, Taiwan and Singapore in the first stage. Subsequently, the Company will develop North American and European markets in the second stage.

This past March, Dragon Jade International announced the appointments of Mr. David P. Bennett, Ms. Suk-Kwan Kwong, and Mr. Marc-Andre Tremblay as new Independent Directors effective upon approval by the Company’s Board of Directors during a Board meeting in February 2019. With the addition of the three new Independent Directors, the Board of Directors also approved the creation of the Nominating Committee and the Compensation Committee. With the changes, the Board now comprises nine members, six of whom are independent.

Dragon Jade International Limited (DGJI), closed Tuesday's trading session at $0.10, up 96.0784%, on 11,000 volume with 3 trades. The average volume for the last 3 months is 2,622 and the stock's 52-week low/high is $0.05/$3.00.

chart

Rhino Resource Partners LP (RHNO)

Zacks, MarketWatch, Mining Connection, GlobeNewswire, Annual Reports, TopPennyStockMovers, Marketbeat, Simply Wall St, 4-Traders, Dividend Channel, Wall Street Mover, and PCG Advisory reported earlier on Rhino Resource Partners LP (RHNO), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, Rhino Resource Partners LP is a diversified energy limited partnership. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. Rhino is a diversified energy MLP (Master Limited Partnership). It produces coal in numerous basins in the U.S. Rhino Resource Partners has its head office in Lexington, Kentucky.

The Company, through acquisitions and other coal lease transactions, has substantially increased its proven and probable coal reserves and non-reserve coal deposits. Furthermore, Rhino has successfully increased its coal production by way of internal development projects.

The Company produces metallurgical and steam coal in an array of basins across the U.S. as well as leases coal. Rhino’s strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost.

Rhino produces steam coal used to produce electricity and metallurgical coal used in the steel-making process. In addition, the Company manages and leases coal properties and collects royalties from such management and leasing activities. Rhino also has oil and gas investments in the Cana Woodford region that provides added cash flows to its business. 

In Central Appalachia, approximately 72 percent of its full-year 2019 thermal and met coal production has been contracted at increased prices in comparison to 2018. Rhino’s Pennyrile, Castle Valley and Hopedale operations are considerably sold out for 2019 at prices that are above the Company’s 2018 levels. Moreover, Rhino has executed long-term contracts with different utility customers for thermal coal for 2020 at Pennyrile and Castle Valley.

Recently, Rhino Resource Partners announced its financial and operating results for the quarter ended December 31, 2018. For the quarter, the Partnership reported a Net Loss of $5.6 million and Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $6.3 million, versus a Net Loss of $18.7 million and Adjusted EBITDA of $6.7 million in Q4 of 2017.

Diluted Net Loss Per Common Unit was $0.49 for the quarter versus Diluted Net Loss Per Common Unit of $1.45 for Q4 of 2017. Total Revenues for the quarter were $64.7 million, with coal sales producing $63.9 million of the total, versus Total Revenues of $55.8 million and coal revenues of $55.4 million in the fourth quarter of 2017.

Rhino Resource Partners LP (RHNO), closed Tuesday's trading session at $0.37, up 146.6667%, on 130 volume with 2 trades. The average volume for the last 3 months is 2,749 and the stock's 52-week low/high is $0.050299998/$1.4397.

chart

Northstar Electronics, Inc. (NEIK)

Penny Stock Tweets, MarketWatch, Stockopedia, Hotstocked, Zacks, InvestorsHub, last10k, Proactive Investors, Financial Buzz, Front Page Stocks, MicroCapSpot, Business Wire, Stockhouse, The Street, YCharts, Capital Cube, Daily Stocks, Marketwired, GuruFocus, Wallet Investor, OTC Watch, and Market Screener reported previously on Northstar Electronics, Inc. (NEIK), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Northstar Electronics, Inc. works in the aviation, defense, and marine industries. The OTCQB-listed Company has a wide-ranging history of developing and manufacturing defense and commercial electronic and mechanical systems. Established in the late 1990’s, Northstar Electronics is headquartered in Virginia Beach, Virginia. Northstar Electronics’ subsidiary is Northstar Sealand Enterprises Ltd. (NSEL).

The Company carried out design and manufacturing contracts for diverse divisions of Lockheed Martin Corp. Additionally, Northstar designed, manufactured, and sold its own sonar-based system to commercial customers.

Northstar Electronics has moved towards making and selling its own independent systems, since the end of the aforementioned contracts. At present, the Company is undergoing restructuring to move forward with a renewed emphasis on the development of a new aviation business and also carry out work to develop unique sonar systems.

Subsidiary NSEL is jointly owned by Northstar Electronics and Sealand Aviation Ltd. Both companies have many years of experience in working with certified commercial aircraft and government military contracts. NSEL is working to acquire the global rights to a “Turbo-Prop” single engine industrial airplane from an international leader in the aerospace industry. The timeline for the final agreement with the subsidiary company that owns the rights to the airplane has been extended.

The chief applications for the airplane are in “Agriculture and Rapid Response Forest Fire Fighting (RRFFF).” NSEL is continuing its evaluation of the “Cloud Seeding” market. Moreover, Northstar sees substantial potential in the field of Counter Insurgency (COIN). Company Management is exploring future possibilities in this sector.

Northstar Electronics is moving ahead with its expansion from being an aerospace contract manufacturer to becoming an “Original Equipment Manufacturer” (OEM) with its own products. The Company made significant progress in the purchase of the worldwide rights to a single engine “Turbo Prop” airplane from a major overseas aerospace company.

Recently, Northstar Electronics provided an update to its shareholders on an important milestone achieved by its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), on a major acquisition. Northstar Electronics and NSEL have been working closely with a major international Aerospace Company with the goal to acquire the international rights and IP (Intellectual Property) for a high-performance Turbo-Prop industrial aircraft.

The Aerospace Company recently presented the main details of this complex transaction to the Canadian government’s Industry, Science and Education Department (ISED). The plan was met with positive and enthusiastic feedback from the department’s representatives.

This confirmation of interest in the transaction, and its eligibility for considerable “Offset” credits under ISED’s Industry Trade and Benefits program, will now accelerate the planned transaction through the Aerospace Company’s internal review processes. Northstar Electronics is moving ahead with its plans to provide financial support for the endeavour. The Company is aligning key investors and financial instruments. NSEL continues its pre-sales efforts and its preparations for a fast and efficient ramp-up to production.

Northstar Electronics, Inc. (NEIK), closed Tuesday's trading session at $0.0066, up 57.1429%, on 6,000 volume with 6 trades. The average volume for the last 3 months is 33,011 and the stock's 52-week low/high is $0.003599999/$0.05.

chart

Regen BioPharma, Inc. (RGBP)

Small Cap Solutions, InvestorTrendz, Insider Financial, TopPennyStockMovers, YCharts, ProTrader, Emerging Growth, SmallCapVoice, Wall Street Mover, TheMicrocapNews, and The OTC Reporter reported earlier on Regen BioPharma, Inc. (RGBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter. 

Regen BioPharma, Inc. is a biotechnology company listed on the OTC Markets’ OTCQB. The Company works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. Its aim is to quickly advance these technologies through pre-clinical and Phase I/II clinical trials.  Checkpoint Immunology, Inc. is a wholly-owned subsidiary of the Company. Regen BioPharma has its head office in La Mesa, California.

At present, Regen BioPharma is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer. Furthermore, it is focusing  on developing stem cell treatments for aplastic anemia. Fundamentally, the Company is working to increase the quality of life through therapies involving small molecules, stem cell treatments, and the body's own immune system.  It is currently developing products treating blood disorders employing small molecules and gene silencing (DiffronC) and treating cancer with immunotherapy (dCellVax). 

Regen BioPharma is also modulating vital molecular processes in cancer stem cells by way of its patented molecular targeting approaches (BORIS). In addition, it is repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). 

Regen BioPharma is centering on small molecules to activate and inhibit its main target of interest, NR2F6. The Company is continuing to develop the NR2F6 program in-house before entering into any potential partnerships. It has granted CheckPoint Immunology an exclusive international license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen BioPharma’s small molecule technology from its other Intellectual Property (IP) to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.

In September, Regen BioPharma reported that its researchers identified a series of small molecule drugs, which inhibit NR2F6 as well as activate human immune cells ex-vivo. Evidence provided by studies suggest that NR2F6 represses the body's immune response against tumors. Therefore, inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor cells.

Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, said, "Based on the known activities of NR2F6, we expect that inhibiting its activity will lead to increased T cell activation. We found that several of our NR2F6 antagonists can activate human immune cells, such as T cells, leading to increased IL-17a production in a concentration-dependent manner."

Recently, Regen BioPharma reported that its researchers determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). Regen will pursue this testing as a joint venture (JV) with Zander Therapeutics, Inc. Zander Therapeutics has been granted an exclusive license by Regen to develop and commercialize the Company's NR2F6 IP for veterinary applications.

Regen BioPharma, Inc. (RGBP), closed Tuesday's trading session at $0.0002, up 100.00%, on 687 volume with 2 trades. The average volume for the last 3 months is 4,436,278 and the stock's 52-week low/high is $0.000000999/$0.002899999.

chart

Vitality Biopharma, Inc. (VBIO)

Penny Stock Tweets, Zacks, The OTC Reporter, Finance Registrar, MarketWatch, GuruFocus, Stock Beast, SmallCap Network, Stockhouse, and Promotion Stock Secrets reported earlier on Vitality Biopharma, Inc. (VBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s dedication is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, the Company has developed a unique capability to produce molecules via glycosylation. This is a form of enzymatic biosynthesis, which was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products. OTCQB-listed, Vitality Biopharma has its headquarters in Los Angeles, California. 

Late in 2015, Vitality successfully modified cannabidiol (CBD), which is not psychoactive. In continuing work, the Company has created a novel class of pharmaceuticals called cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Vitality Biopharma can biosynthesize cannabinoid glycosides (cannabosides) via enzyme biosynthesis. The Company is one of only a very few groups in the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of stevia (steviol glycosides). 

Vitality Biopharma has developed a proprietary biosynthesis technology that can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds called cannabinoid glycosides, or cannabosides.

The Company has introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. Vitality is centering initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation. The treatment indications it plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome (a severe form of opiate-induced abdominal pain).

Vitality Biopharma announced in April 2018 the pending establishment of a wholly-owned Canadian subsidiary, Vitality Genetics, Ltd. This subsidiary will focus on and enable the performance of a wide assortment of cannabinoid genetics research and development (R&D) programs.

Vitality Biopharma announced in May the discovery of new antimicrobial activity of cannabinoids and its application for treatment of C. difficile-associated diarrhea and colitis. In experiments executed according to guidance by the Clinical Laboratory and Standards Institute (CLSI), Vitality determined that cannabinoids (including THC) are effective antibiotics for C. diff, VRE, and a variety of additional pathogens.

Recently, Vitality Biopharma announced that during a recent in vitro safety pharmacological screening study, its lead drug candidate VBX-100 demonstrated no signs of adverse pharmacological effects. This affirms its potential for extensive clinical use as a GI-targeted prodrug of THC. Vitality Biopharma has filed for intellectual property (IP) protection on greater than 100 different glycoside prodrugs. This includes VBX-100.

Vitality Biopharma, Inc. (VBIO), closed Tuesday's trading session at $0.1499, up 57.7895%, on 97,035 volume with 52 trades. The average volume for the last 3 months is 24,331 and the stock's 52-week low/high is $0.0051/$0.349999994.

chart

The QualityStocks Company Corner

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX) is positioned for opportunity in the business of big data, leveraging technology that unlocks information to reveal brands’ core consumers and their characteristics across several marketing channels. SRAX’s BIGtoken platform integrates all aspects of the advertising experience into a one-stop shop and allows monetization of specialized data sets across several verticals. To view the full article, visit: http://nnw.fm/S45Dw

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $2.44, up 6.087%, on 16,251 volume with 86 trades. The average volume for the last 3 months is 69,757 and the stock's 52-week low/high is $1.04999995/$4.80499982.

Recent News

chart

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B)

The QualityStocks Daily Newsletter would like to spotlight Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B).

Bullfrog Gold Corp. (BFGC:OTCQB; BFG:CSE; 11B:FSE) (“Bullfrog,” “BFGC” or the “Company”) today announced assay results from the six remaining holes of the 25 total holes recently drilled at its Bullfrog Project (“Project”). The Project comprises 2,125 hectares (5,250 acres) of strategic lands, established resources and prospective exploration potential in the Bullfrog Mining District located 4 miles west of Beatty, Nevada (200 km northwest of Las Vegas, Nevada). The Bullfrog and surrounding area are in one of the most prolific gold exploration regions in North America that includes significant activities by neighboring AngloGold, Kinross Gold, Coeur Mining and Corvus Gold. The Company has commanding land and resource positions in the Bullfrog mine area and obtained Barrick Bullfrog Inc.’s (Barrick) large database, including detailed information on 250,000 meters (155 miles) of drilling in the area.

Bullfrog Gold Corp. (the “Company”) (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States. The Company controls strategic lands with established 43-101 compliant resources in one of the most exciting gold exploration areas in the United States. The Bullfrog Gold Project (“Project”) includes a lease/option on much of the lands where Barrick Bullfrog Inc., a subsidiary of Barrick Gold Corp., produced more than 2.3 million ounces of gold and 2.49 million ounces of silver from 1989 to 1999. The Project is located within the prolific Walker Trend about 125 miles northwest of Las Vegas, Nevada.

Project Highlights

  • The Company initially acquired 79 unpatented claims and two patents in mid-2011 and has since staked, leased, optioned, or purchased lands that now total 5,250 acres. Via a 2015 lease/option with Barrick, the Project includes the northern one-third of the Bullfrog deposit where most of the current resources in the Bullfrog mine area occur, along with their interest in the Montgomery-Shoshone deposit which gave the Company 100% control.
  • In mid-2017, a NI 43-101-compliant report by independent mining consultancy Tetra Tech Inc. estimated measured and indicated (“M&I”) resources of 624,000 ounces of gold and 1.73 million ounces of silver at average grades of 0.70 g/t and 1.93 g/t, respectively. The expansion plans of these two pits were based on a $1200 gold price, use of heap leach processing, and also included 110,000 ounces of inferred gold resources averaging 1.20 g/t. Barrick used conventional milling to process an average gold grade of 3 g/t.
  • The established resources and exploration potential of the Project are strongly supported by a large data base obtained from Barrick, including detailed information on 155 miles of drilling in 1,262 holes in the Bullfrog mine area.

Gold Rush in the Bullfrog Territory

The area around Beatty, Nevada has now attracted AngloGold Ashanti, Kinross Gold, Corvus Gold, Coeur Mining as well as the Company and Waterton. In this regard, Northern Empire Resources Corp’s property located a few miles east of the Project was acquired by Coeur Mining in October 2018 for C$117 million, implying a valuation of C$134/oz of inferred resources. As of today, the Company is trading at a significant discount to the valuation at which Northern Empire was purchased (http://nnw.fm/9NaaN), thereby highlighting the Company’s value proposition for investors.

Bullfrog Gold Corp. is focused on enhancing shareholder returns by concurrently advancing Project development and performing exploration drilling programs on several targets identified by the Company.

Secured Financing for 2020 Operations

Bullfrog Gold Corp. raised C$2 million in January 2020 through a private placement of shares priced at C$0.13/share plus a one-half warrant exercisable within two years at C$0.20 on a full warrant basis. The raise was carried out primarily to fund a drill program that started on May 1 (http://nnw.fm/6nZ0m), and was completed on June 6, 2020. Results from drilling 12,520 feet in 25 holes will be released in the coming weeks. The Company subsequently intends to conduct a preliminary financial analysis and complete further drill programs to advance the Project and add value. The financing was subscribed by several influential shareholders, including a former director of Northern Empire, who handled the sale of the company to Coeur Mining, and Eros Resources, the management of which has been involved with several high-profile mining projects and sales in the past.

Gold Prices estimated to average $1,800/oz in 2021

Gold prices have been on a remarkable run in 2020, rising by $245/oz to $1,760 prior to peaking in early May. Global central banks carried out 144 interest rate cuts thus far in 2020, reducing their rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the COVID-19 pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures prompted Credit Suisse to recently hike their gold price forecasts for the full year to $1,701/oz (from $1,570 previously), while the outlook for 2021 has been raised to $1,800/oz (versus $1,600 previously) (http://nnw.fm/Iqg0X).

Management Team

David Beling, CEO, President and Director
David Beling is a Registered Professional Mining Engineer with 55 years of diverse experience in areas such as engineering, development, permitting, construction, financing and management of mines and plants and the building and growth of several corporations. His initial employment included 14 years with Phelps Dodge, Union Oil, Fluor, United Technologies, and Westinghouse, followed by 41 years of senior management and consulting with 25+ U.S. and Canadian mining companies. In 2006-2007, he spearheaded an IPO, successfully drove equity raises totaling C$112 million and grew that Company’s market capitalization to $460 million. Beling has served on 14 boards since 1981, including three mining companies distinguished by the TSX Venture Exchange as top-10 performers.

Alan Lindsay, Chairman of the Board
Alan Lindsay is an entrepreneur and businessman who has founded seven companies within the mining and pharmaceutical industries, including Anatolia Minerals Development Ltd., Uranium Energy Corp., Oroperu Mineral, Strategic American Oil and AZCO Mining. Lindsay also developed the strategic vision for the 2011 acquisition and placement of the Project from NPX Metals into Bullfrog Gold Corp.

Kjeld Thygesen, Director
Kjeld is a graduate of the University of Natal in South Africa and has 48 years of experience as a resource analyst and fund manager. In 1972, he joined James Capel and Co. in London as part of its highly rated gold and mining research team before subsequently becoming manager of N. M. Rothschild & Sons’ commodities and Natural Resources Department in 1979. In 1987, he became an executive director of N. M. Rothschild International Asset Management Ltd., before co-founding Lion Resource Management Ltd., a specialist investment manager in the mining and natural resources sector, in 1989. Thygesen has been a director of Ivanhoe Mines Ltd. since 2001 and served as investment director for Resources Investment Trust PLC from 2002 to 2006.

Tyler Minnick, CFO and Director of Administration & Finance
A registered member of the Colorado Society of Certified Public Accountants with over 24 years of experience within the fields of accounting, auditing, and administrative services. Minnick has been engaged with the Company since mid-2011 and previously worked in the finance department of MDC Holdings/Richmond American Homes, one of the largest residential construction companies in the United States.

Bullfrog Gold Corp. (OTCQB: BFGC), closed Tuesday's trading session at $0.17, up 10.3896%, on 570,135 volume with 118 trades. The average volume for the last 3 months is 171,703 and the stock's 52-week low/high is $0.047449998/$0.209999993.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.44, even for the day, on 1,034,301 volume with 2,114 trades. The average volume for the last 3 months is 1,009,685 and the stock's 52-week low/high is $1.25/$7.90000009.

Recent News

chart

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth (NASDAQ: DRIO) is a pioneer in the global digital therapeutics market focused on delivering evidence-based interventions to people with chronic conditions. A recent article discussing DarioHealth reads, “Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.” To view the full article, visit: http://ibn.fm/QtIUL

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Tuesday's trading session at $6.40, off by 8.5714%, on 52,543 volume with 221 trades. The average volume for the last 3 months is 72,731 and the stock's 52-week low/high is $3.01999998/$13.1260004.

Recent News

chart

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA)

The QualityStocks Daily Newsletter would like to spotlight PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA).

Disruptive fintech innovator PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) announced July 13 that its U.S. leasing division, MUSA Auto Finance, LLC, have begun originating auto loans in Texas and Florida and will soon add California and other states’ markets after gaining $300 million in lease financing from a federally chartered U.S. depository financial institution for its online leasing platform (http://nnw.fm/JQ33a).

A Better Way to Connect and Acquire Vehicles

PowerBand’s mission is to create an online, consumer-directed marketplace that streamlines the interactions among all participants in the automotive industry. It transforms today’s antiquated business model with speed, transparency, access to information and ease of use for consumers and dealers.

Consumers can easily connect with new sources to buy vehicles, network with motivated buyers and sellers, maximize their trade-in values, improve their customer experience. PowerBand’s standardized system and transaction process also increase efficiencies and benefits with hands-on, process-driven, in-store training and support.

Through internal development, acquisitions, joint ventures and strategic partnerships, PowerBand is developing solutions for consumers, dealers, manufacturers, commercial customers and lenders that are poised to transform the trillion-dollar U.S. automotive industry.

The PowerBand Auto Platform

PowerBand’s transaction platform was developed by a team of experienced automotive, technology and finance experts, and has been refined through years of operational experience. Built on the core belief that the consumer prefers to primarily conduct automotive transactions online and avoid interactions with unnecessary middlemen, PowerBand’s product solutions include:

  • Leasing: PowerBand is currently licensed in 33 U.S. states via a majority interest in MUSA Auto Finance LLC, an advanced online leasing technology platform that has transformed the new and used vehicle leasing industry. A partnership with Tesla was recently finalized, making MUSA the only approved, non-captive lease partner for Tesla in the U.S.
  • Inventory and Financing: A partnership with RouteOne LLC, a leading financial platform founded in 2002 by Ally Financial, Ford Motor Credit Co., TD Auto Finance and Toyota Financial Services, allows access to a network of more than 18,000 dealerships and 1,400 financing sources.
  • Auction Platform: PowerBand and its joint-venture partner, D2D Auto Auctions, are developing a direct consumer-to-dealer and a consumer-to-consumer automotive portal, which will provide an innovative alternative to physical dealership and auction locations.
  • LiveNet Auction: An online platform portal that allows dealers to create instant live vehicle auctions to a vast network of the industry’s top used vehicle buyers.
  • MarketPlace Auction: An online listing auction site for buying and selling automotive inventory – ideal for dealers, fleet, OEM and rental companies.
  • Used Vehicle Inspections: An LOI agreement with TÜV NORD Mobility Inc., a German-based global leader in vehicle inspections operating in more than 70 countries, will provide the most comprehensive, certified vehicle inspection reports available in North America. Appointments booked within the platform can be performed nearly anywhere.
  • Product Development: PowerBand’s comprehensive consumer solution, Driveaway, will be a fully transactional consumer marketplace where dealers and consumers can buy, sell, trade-in and finance vehicles, often in seconds, from the comfort of their home.

Automotive’s Growing Markets

The automotive dealership and commercial fleet vehicle auction industry is a $100-billion sector with more than 40 million used vehicles transacted in the U.S. each year. Of those, ten million are sold through auctions. From 2013 to 2017, the growth of online-only auctions far outpaced physical auctions, growing at a 33% compound annual growth rate compared to 2% CAGR at physical auctions.

Automotive leasing is another large, growing and fragmented market, generating approximately $120-billion in annual revenue. As a percentage of vehicle sales, leasing reached 30% in 2018, up from 21% in 2012, and is seen as a substantial opportunity for PowerBand and MUSA Auto Finance. Using proprietary technology and by focusing on high-quality, credit-worthy customers, MUSA grew its automotive lease originations to $182 million.

Disrupting Auto Leasing with MUSA

Legacy solutions are complicated, expensive and slow at processing leases. MUSA’s first-of-its-kind technology platform eliminates third-party decisions and the human capital required in the underwriting process. MUSA’s platform navigates the entire customer experience – underwriting, funding and the delivery process – within minutes. Leases can be approved in seconds.

PowerBand’s acquisition of MUSA brings together two leading-edge companies with the vision to become a one-stop platform for the entire vehicle purchase lifecycle.

Experienced Leadership

PowerBand is led by a collection of automotive veterans with a passion to collectively and positively impact the industry.

  • Kelly Jennings, president and CEO, is the founder of PowerBand Solutions and a franchise dealer owner/operator with more than 27 years of automotive experience. Jennings received General Motor’s Triple Crown Award, Ford Motor Company President’s Award and Honda Canada’s Excellence Award.
  • Darrin Swenson, COO of PowerBand and D2D Auto Auctions/Hunt Automotive Group, has more than 25 years of automotive/auction experience.
  • Jeff Morgan, CEO MUSA, holds over 25 years of experience in the auto finance sector.

 

PowerBand Solutions Inc. (OTCQB: PWWBF), closed Tuesday's trading session at $0.201, off by 8.5116%, on 75,504 volume with 38 trades. The average volume for the last 3 months is 84,796 and the stock's 52-week low/high is $0.038600001/$0.241600006.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp branded products company in the U.S., today announced the launch of its new HI-CUBES brand into the California adult-use market. According to the update, HI-CUBES is the most concentrated gummy product (“THC” by volume) available in the California market*, and its 100% whole plant, full-spectrum oil delivers cannabinoids, flavonoids and aromatic terpenes for a more dynamic high. “Following the launch of our PLUS CBDRelief brand this past February, we are excited to further expand our portfolio to ensure that consumers looking for all different types of experiences can turn to our brands for their cannabis needs,” Jake Heimark, co-founder and CEO of Plus Products, stated in the news release. To view the full press release, visit http://cnw.fm/g761M

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $0.4131, off by 4.375%, on 102,370 volume with 72 trades. The average volume for the last 3 months is 33,639 and the stock's 52-week low/high is $0.279000014/$4.03999996.

Recent News

chart

The Movie Studio Inc. (OTC: MVES)

The QualityStocks Daily Newsletter would like to spotlight The Movie Studio Inc. (OTC: MVES).

The Movie Studio (OTC: MVES) looks to be in the right place at the right time with the video on demand (“VoD”) market projected to reach anywhere from $80 billion (http://nnw.fm/J3Xk3) to $120.91 billion (http://nnw.fm/WXCp5) by 2025. To view the full article, visit: http://nnw.fm/zX7uv.

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on acquiring, developing, producing and distributing independent motion picture content for worldwide consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales and various media devices. The company is currently engaged in establishing its own OTT VOD platform to integrate both its own and aggregated feature film projects, television programming and other media intellectual properties. The Movie Studio is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and the company intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution.

The company has launched The Movie Studio App on Google Play and the App Store, enabling users to both view the company’s content and potentially become part of it. The app is in the completion stage, and The Movie Studio is conducting its final beta test of the app’s unique “audition submission” function, leveraging the company’s “Watch Our Movies, Be in Our Movies!” content platform and “Everyone’s a Star” campaign, which will be marketed via social media. Using the app, subscribers can upload a thumbnail photo of themselves along with a selfie video audition submission that showcases them reading character dialog. Audition submissions will then be reviewed by producers for possible participation of the auditionee in upcoming feature films.

The audition submission function provides the subscriber the ability to disrupt traditional motion picture casting and management, enabling access to participation in The Movie Studio’s independent motion picture and media content. At the same time, for the company this significantly reduces capital expenditures associated with those traditional media mechanisms. The Movie Studio’s unique business model capitalizes on the global demand for film content through the production and distribution of its own films while also providing opportunities for direct viewer involvement in its content.

The company operates using a growth-by-acquisition strategy that includes:

  • Purchasing legacy film libraries.
  • Upgrading acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the internet.
  • Strategic partnerships and media content alignment with other OTT platforms and cross-collateralization of leverageable media assets for worldwide distribution.
  • Producing micro-budget motion picture content with substantial production value utilizing new 4K technology and the company’s extensive legacy resources and unique production process, thereby significantly reducing capital expenditures while allowing for the potential of significant return on investment (ROI) with one successful production.
  • Controlling its revenue streams through server-driven geo-fracturing global territories and its own OTT platform.

Currently, The Movie Studio is producing three upcoming feature films: “Cause and Effect,” “The Last Warhead” and “PEGASUS” — all with completed electronic press kits and pitch decks and fully produced motion picture-quality trailers ready for talent, distribution and financial integration.

The company has been successful in producing, casting and distributing its films on major SVOD platforms without recognizable stars, which reduces capital expenditures. However, The Movie Studio intends to integrate recognizable stars into the productions at value propositions either pre- or post-completion of the intellectual property.

Through successful beta testing, The Movie Studio has monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The company’s proposed server-based model will provide licensing payment from global territories without third-party distribution fees, which have traditionally been as high as 35%.

Founded in 1961 and formerly known as Destination Television, Inc., the company changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio is headquartered in Fort Lauderdale, Florida.

Cord-Cutting Creates Opportunity for VOD Players

Consumers are no longer content waiting for their favorite programming to come on the air – they expect instant streaming access where and how they want it. This has led to increased “cord cutting,” with consumers severing ties with their traditional pay TV providers in favor of digital streaming services.

With the advent of smart TVs with app integration, consumers can now watch what they want to watch when they want to watch it, fracturing traditional cable bundling mechanisms.

With pay TV usage steadily declining – satellite and cable TV businesses in the United States lost approximately 6 million customers in 2019 alone – streaming platforms are poised to potentially replace traditional pay TV distribution models altogether. Approximately 12,000 U.S. consumers are cutting the cord every day.

As this shift in media delivery continues and as digital devices become more sophisticated and bandwidth increases, VOD platforms have the potential to scale significantly. The Hollywood “streaming wars” of recent years have created an environment in which smaller competitors, like The Movie Studio, are able to emerge as major brands.

The Movie Studio Inc. (OTC: MVES), closed Tuesday's trading session at $0.01, off by 8.2569%, on 33,297 volume with 6 trades. The average volume for the last 3 months is 164,510 and the stock's 52-week low/high is $0.006099999/$0.07.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (SGMD) was highlighted today in a publication from JournalTranscript.com, examining how the analyst community has finally started to warm back up to the pot stock space in recent action. This shift can be seen in numerous price target adjustments and perhaps most notably in the signature upgrade out to start this week from Stifel analyst W. Andrew Carter, who raised Aphria Inc (NASDAQ:APHA) from a Hold to a Buy and said the stock could launch up to $5.90 per share. It was a valuation upgrade, but it sent a wave of energy through the cannabis space because it suggests increasing attention being paid to the space again by major firms.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Tuesday's trading session at $0.003, off by 3.2258%, on 76,803,446 volume with 425 trades. The average volume for the last 3 months is 58,463,545 and the stock's 52-week low/high is $0.001599999/$0.021999999.

Recent News

chart

iClick Interactive Asia Group Ltd. (NASDAQ: ICLK)

The QualityStocks Daily Newsletter would like to spotlight iClick Interactive Asia Group Ltd. (NASDAQ: ICLK).

iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced  that its management team will give a company update and share their current views on the industry  in a virtual Tech Talk hosted by Brian Kinstlinger, Head of Technology Research at Alliance Global Partners on July 16, 2020 beginning 10:00 a.m. EDT. Please register for the Tech Talk with the link: http://ibn.fm/6MMNt.

iClick Interactive Asia Group Ltd. (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider connecting worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfills various marketing objectives in a data-driven and automated manner, helping international and domestic marketers reach their target audiences. Headquartered in Hong Kong, iClick operates in 10 locations worldwide, including Asia and Europe.

iClick aims to become a fully integrated Enterprise and Marketing Cloud Platform in China, providing clients a full consumer-cycle solution. This is facilitated by two pillars’ growth strategy through two business segments: Marketing Solutions and Enterprise Solutions.

Marketing Solutions

Using data and AI-driven technology to help brands efficiently identify, target and acquire the right customers

As the leading programmatic marketing platform in China, iClick’s proprietary platform collects a wealth of data from multiple sources to precisely reach the right audience at the right moment, on the right channel and right device. Cross-screen search solutions capture critical micro-moments when users proactively search for what they need. This multi-dimensional approach to marketing allows iClick to effectively understand internet users and exponentially widen target audiences for its brand clients. Multiple monetization models available in the Marketing Solutions segment allow iClick to serve its clients in several ways, such as audience targeting.

Data-driven marketing is indispensable to marketers targeting specific audiences in China. More than 825 million internet users in China are anonymously profiled on iClick’s platform, which boasts cross-channel and cross-screen capabilities.

Enterprise Solutions

Enabling brands to efficiently manage their consumers through online and offline data integration and analysis, increase the repurchase rate, and enhance consumers’ loyalty

iClick’s Enterprise Solutions segment addresses enterprise needs in China, particularly focusing on “smart retail,” an expanding and innovating market involving the combination of online and offline consumers’ behavioral information. Enterprise Solutions support detailed profiling of customers, which facilitates data-driven business strategies, enhances business processes at various levels, and increases operational and marketing efficiency.

Enterprise Solutions leverages iClick’s proprietary platform that incorporates Artificial Intelligence (AI) to learn, build and store knowledge, enabling accurate predictions about consumer behavior that ultimately provide marketing solutions derived from the large amount of available data.

Through a strategic partnership with Tencent, iClick’s Enterprise Solutions presents strong recurring revenue streams with tremendous opportunities to upsell multi-national corporations (MNCs). Tencent’s proprietary API connection enables brands to build 360-degree consumer profiles based on the collection and integration of purchased behavioral information from online and offline touchpoints, including WeChat Mini Programs, WeChat Payment, WeChat Work and more.

As iClick continues to provide integrated marketing and smart retail solutions targeting Chinese consumers, the company believes Enterprise Solutions has strong long-term growth potential and will become a major gross margin contributor in the future.

Partnerships

In 2019, iClick established various agreements and partnerships with a number of leading southeast and northeast Asian companies for regional diversification and in 2020 is focused on continuing to develop additional partnerships and new business models globally. Many of the world’s top companies are leveraging iClick’s proprietary data platform to precisely identify and reach out to core target audience groups in China.

The company’s partnerships include:

  • A tri-partnership with BTG WELINK, an online retail services arm of Beijing Tourism Group (“BTG”), and Tencent Holdings Ltd., China’s leading provider of internet value added services. As part of this partnership, iClick applies its upgraded solutions to build a private DSP (Demand Side Platform) system for BTG. Using Tencent’s big data advertising platform, iClick can assist BTG to develop precision marketing campaigns.
  • An Advertising Agency Authorization Certificate from Baidu Inc. (NASDAQ: BIDU), under which iClick is designated the authorized agency for native advertising of Baidu’s news feed ads. Native advertising is a consumer-friendly, non-disruptive advertising format that has gained rapid popularity among advertisers in recent years. Native advertising and creative marketing content have become a more effective marketing method among the Chinese young consumers. In 2019, the native advertising sector was estimated to have an around 53.5% share of the online advertising revenue, according to Statista.
  • A joint-venture partnership with VGI Global Media Plc (VGI.BKK), Thailand’s No. 1 online to offline (O2O) solutions provider across advertising, payment and logistics platforms, which enables brands in Southeast Asia to capture the multi-billion-dollar Chinese consumer market through a range of technology-driven marketing solutions.

Case Study: Armani Hotel Dubai

Dubai has been gearing up to welcome the growing wave of Chinese visitors. Chinese nationals are eligible for a 30-day visa-on-arrival into the UAE, which gives Chinese travelers tremendous convenience. In light of this, Armani Hotel Dubai set the objective to increase its sales in this market.

The challenge: What Aarmani Hotel Dubai lacked in executing this goal was insightful understanding of Chinese travelers in particular the demographics that were likely to be attracted to the hotel. Challenged by the huge differences in the business practice, unique culture and language barrier in running digital campaigns in China, Armani Hotel Dubai turned to iClick’s know-how and expertise to guide its campaign to success and meet its sales goal.

The solution: iClick tailored an optimal solution for the hotel to increase brand awareness and booking rate from China – which is the key market for the hotel – and successfully assisted Armani Hotel Dubai in reaching its target Chinese audiences by using China’s most popular mobile and internet sites, including WeChat and Weibo, to improve reach and booking potential.

The results: Due to iClick’s unrivaled technological and execution strengths, Armani Hotel Dubai’s ads were delivered in an omnichannel manner, raising brand awareness and garnering interest between Chinese consumers. Subsequently, Armani Hotel Dubai saw a surge in conversion rate.
During the campaign, the Armani Hotel Dubai brand was connected with 87% of Chinese mobile users.

Award-winning Provider

iClick, a Deloitte Technology Fast50, has received multiple industry awards from the international marketing community. The company is committed to helping clients access digital China with its omni-channel, data-driven marketing solutions that deliver uniquely sharpened marketing capabilities and outstanding advertising results.

Most recently, iClick subsidiary OptAim (Beijing) Information Technology Co., Ltd was recognized by Tencent Ads as a 2019 Gold Service Provider. Tencent Ads also named OptAim the winner of three major annual awards for the second half of 2019: “Outstanding Contribution of the Year,” “Best Technology & Data Application Award,” and “Best Branding Awards.”

In November 2019, company co-founder and CEO Sammy Hsieh was chosen as the winner of the “EY Entrepreneur of The Year China 2019 Award in Technology Category,” an award recognizing his entrepreneurial acumen, innovative spirit and strong leadership. As one of the world’s most prestigious business accolades, the “EY Entrepreneur of The Year” awards program honors those who accomplish success by combining ability with opportunity, and inspire others with great vision, leadership and outstanding achievement.

iClick won the Annual Influential Platform Award and the Innovation Golden Award in Marketing at the Creative Award 2019, as well as the Best Tourism Marketing Agency. The company was also the recipient of the “Best Brand and Performance Marketing Award” at the Performance Marketing Ecosystem Summit 2018 hosted by the Advertising & Marketing Service, a division of Tencent Holdings Limited.

The company in 2018 was also recognized as “Platinum Service Partner of Tencent Social Ads” at the Tencent Key Accounts Mid-Year Summit held in Beijing. The mobile division of iClick, Optaim, received the same award beginning in 2016. Optaim was also the “Best DSP Partner” and “Key Account Data Partner” of Tencent, making it the only player in China with such unique and deep level of cooperation with Tencent Social Ads.

Leadership

Sammy Wing Hong Hsieh, chairman of the board and co-founder, was CEO from 2009 to 2019. Prior to co-founding iClick, Hsieh held senior positions in several prominent technology companies. He was general manager for Asia Pacific at Efficient Frontier (now an Adobe company), a leading digital performance marketing company, and was director of Search Marketing at Yahoo Hong Kong from 2000-2008. Hsieh received a bachelor’s degree in economics from the University of California, Los Angeles.

Jian Tang, director, CEO and co-founder, has 20 years of experience in digital advertising and is well-known in China for his expertise in advertising technologies and big data. In 2012, he founded OptAim, which was acquired by iClick in 2015, and has served key research, engineering and management roles at Yahoo’s global research and development center. Tang received his doctorate in computer engineering from Tsinghua University and was named by Campaign Asia as one of the leaders in its Digital A-List in 2016.

Terence Chi Wai Li, chief financial officer, has 15 years of experience in financial management, investment and business operations. He has served in management roles and advisory capacities at several start-ups, in addition to financial management and fundraising roles. He previously worked at PricewaterhouseCoopers, specializing in M&A due diligence and cross border tax and deal structuring projects. Li received an MBA from Oxford University’s Said Business School. He is a Fellow Member of ACCA, a Member of HKICPA, and a Chartered Financial Analyst.

iClick Interactive Asia Group Ltd. (NASDAQ: ICLK), closed Tuesday's trading session at $5.30, off by 0.749064%, on 455,661 volume with 2,438 trades. The average volume for the last 3 months is 521,904 and the stock's 52-week low/high is $2.73000001/$5.98999977.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) was featured today in the 420 with CNW by CannabisNewsWire. For the past three or so decades, the federal government has punished individuals charged with marijuana possession quite harshly. Ever since the ‘War on Drugs’ began, certain communities have been unfairly stereotyped, targeted and punished for marijuana offenses. Although people of all races are likely to purchase and consume cannabis, people of color are much more likely to be arrested and prosecuted compared to other races. Proponents for marijuana legalization have argued that decriminalizing marijuana will go a long way in righting these wrongs.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Tuesday's trading session at $0.0161, off by 5.2941%, on 332,720 volume with 63 trades. The average volume for the last 3 months is 1,115,892 and the stock's 52-week low/high is $0.0092/$2.15000009.

Recent News

chart

ISW Holdings (ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings (ISWH).

ISW Holdings (ISWH) (“ISW Holdings”) is a brand management portfolio company with diverse partnerships that focus on growing businesses in multiple sectors, including crypto mining, renewable energy, home health care for the chronically ill, wellness and restoration, and the adult beverage industry, as well as early-stage operations in supply chain and logistics management. ISW Holdings operates as the nexus between its partnerships and their essential services for end users.

Mission
The company’s core mission is to enhance these sectors by implementing innovative services and products ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources, and innovative software to establish market-leading companies and partnerships, which ensure their success in their chosen industries. This enables the company to return maximum shareholder value with its focus always on its partnerships’ various sector volatility.

The Revolution
Positioned to create industry leaders, the company’s process entails strategic development and aggressive early growth of its partner brands to establish them as profitable and viable. ISW Holdings’ method is to nurture emerging partner brands through the essential stages of market development (from conceptualization to distribution) in sectors relevant to today’s marketplace. In addition, the company has a holistic approach to business development, with every strategy being delivered person-to-person from developers to end users.

The Challenge
The company’s goal is to turn its target audience into loyal consumers by ensuring transparency and a clear understanding of its products and services, thus creating visibility, credibility, and trust.

ISW Holdings’ Innovative Approach
ISW Holdings has diversified positions in its partnerships across technology, health care, wellness, renewable energy, and the adult beverage sectors. The company seek to provide industry leading modern solutions to its clients and sound business practices to its partners. This is accomplished through an early growth platform that cultivates its partnerships with the necessary resources and expertise to expand exponentially.

ISW Holdings’ Opportunity
The company’s opportunity is considerable. In the ever-changing high demand global marketplace, the need for timely innovation is critical. ISW Holdings’ portfolio brand management and creative thinking has allowed the company to develop and deploy enterprises that meet the needs of 21st century consumers. Through a fully vetted system of scalability, it is able to meet consumer demands with turn-key solutions.

Portfolio of Partnerships and Businesses
ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. With partnerships that incorporate a depth of experience and industry insight, ISW Holdings has established itself as a portfolio company in technology, home health care, and wellness, with a focus on reshaping industry benchmarks.

Bit5ive

ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. As an official distribution partner of Bitmain (the industry’s leading fabless manufacturer of computing chips and distributor of Antminers to more than 30 countries in Latin America, Central America, and the Caribbean), Bit5ive is quickly becoming one of the largest U.S.-based companies in the cryptocurrency mining and bitcoin farm sectors of the market.
Valued at $293.66 million in 2019, the bitcoin technology market is expected to reach $477 million by 2025, according to Mordor Intelligence. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.

Proceso, LLC

With a growing awareness of the importance of renewable energy worldwide, ISW Holdings has partnered with Proceso, LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining – two fields with a typically high energy demand.

Because crypto mining companies mostly operate outside of the United States with higher asset security risks, Proceso will assist these entities in securing their investments by providing a local source of power and infrastructure development. This is aimed at helping to reduce power consumption while creating secure crypto mining data centers in the U.S. For the gaming industry, Proceso is ready to tackle one of its biggest problems, latency, by building next-level infrastructure in key locations.

PHH – Home Health

PHH Paradigm Home Health answers the growing need for homecare services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care. PHH aims to be at the forefront of this change by offering quality care services infused with new emerging technologies.

ISW Holdings’ home health division is currently developing a pilot for on-demand health care, which consists of a dedicated, stable platform for different medical services. The platform will offer greater freedom of choice and transparency by allowing users to find outpatient clinics in their vicinities, compare costs, and pick the most suitable choices. PHH is also developing specialized technology and tools to support health care services outside of the bounds of specialized facilities by focusing on homecare facilities. This can not only shift the burden from hospitals and clinics, but also streamline specific parts of the health care process to enhance service and product distribution.

VOLUM

ISW Holdings’ logistics and supply chain management division was designed with the core goal of increasing supply chain efficiency as one of the key aspects of successfully growing any business. The VOLUM project’s focus is on identifying and then implementing advanced supply chain management strategies and methods that will enable ISW Holdings’ partner companies to scale and grow exponentially. To achieve this goal, the company develops and offers reliable systems and solutions that create innovative technologies and unmanned system operations for overall higher cost-effectiveness.

In the wellness sector, ISW Holdings has opted for a two-pronged approach to create effective, technologically advanced products, as well as developing innovative ways to educate customers about these products. To this end, ISW Holdings has partnered with BioPulse to achieve state-of-the-art research and development and production capabilities, as well as a direct route to market. The company plans to design and launch up to five unique brands in the wellness and restoration sector in 2020.

ISW Holdings is committed to developing product and service innovation in the consumer spirits and adult beverage industry, which faces increasingly strict regulations but growing demand. The company has been a key innovator in the industry for 25 years, having grown successful luxury brands such as Besado Tequila and others. By leveraging its expertise, ISW Holdings can help companies in the adult beverage industry increase production, streamline their supply chains, implement better processes, innovate their marketing strategies, expand into new areas, and build sustainable relationships with partners and customers.

Management Team

Terry Williams, Chief Executive Officer and Director
Terry Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance, and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, Williams amassed considerable corporate experience at United Parcel Service, where he took several logistical roles, including controller, where he managed more than 2,000 employees and a budget of more than $10 billion.

Williams also serves as president of Airwave Transportation and logistics and chief financial officer of AVI Insurance Caribbean, and he has worked in over 37 domestic and international airports. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce, Chairman
Alonzo Pierce is chairman of ISW Holdings and brings a wealth of business development and wealth management experience to the ISW team. He has spent the past 20 years building recognizable brands in multiple industry sectors. He has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands, including selling the world’s only black vodka. He served as regional director for Sapphire Brands, covering the Southwest and Southeast regions. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown, Secretary, Treasurer, Director
Kristina Mahoney-Brown is secretary and treasurer as well as director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings (ISWH), closed Tuesday's trading session at $0.2295, up 35.00%, on 16,093 volume with 19 trades. The average volume for the last 3 months is 21,049 and the stock's 52-week low/high is $0.109999999/$8.00.

Recent News

chart

Pure Extracts Corp.

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Corp..

Pure Extracts, a private, plant-based extraction company, is focused on becoming a dominant extraction company in the functional mushrooms market, as well as a leader in the rapid development and commercialization of products in the emerging sector. To view the full article, visit http://ibn.fm/oLXE6

Pure Extracts Corp., headquartered in Pemberton, British Columbia, is a private, plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extract is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.


Recent News

chart

Cybin Corp.

The QualityStocks Daily Newsletter would like to spotlight Cybin Corp..

For decades seen as a taboo substance, psychedelics today are being viewed in a powerful new light. This significant societal switch is based, at least in part, on credible clinical studies, which have shown that serotonergic psychedelics may be effective in treating anxiety, depression, addiction and even cancer (http://ibn.fm/mSzY5). Cybin Corp., a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, appears to be a strong player in this developing new space.

Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.


Recent News

chart

Deltec Bank & Trust Ltd.

The QualityStocks Daily Newsletter would like to spotlight Deltec Bank & Trust Ltd..

As a leading financial hub for the global investment, finance and entrepreneur community, Deltec Bank & Trust offers specialized financial solutions and institutional expertise with the primary goal of creating opportunities for its clients to enhance their wealth. As part of its service offerings, the company recently released a special report (http://ibn.fm/7Ig6O) outlining details of the U.S. government’s $2.2 trillion Coronavirus Aid, Relief, and Economic Security (“CARES”) stimulus package. The timely piece includes commentary concerning the potential effects to US personal incomes should the unemployment insurance benefits be allowed to expire at the end of the month without extension.

Deltec Bank & Trust Ltd. is a leading financial hub for global investors, financiers and entrepreneurs. The private and corporate bank offers its clients a unique suite of bespoke financial solutions, institutional expertise and highly attentive service with an aim toward creating a network of opportunities to enhance client wealth. Deltec Bank & Trust Ltd. is the flagship company of the Deltec International Group, a diversified independent financial services group providing a range of financial services including fund administration, corporate advisory, merchant banking, global insurance and digital asset solutions.

Founded in 1959, Deltec draws upon the collective experience of more than 150 professionals. These specialists come from a wide array of backgrounds, including private bankers and investment advisors, trust officers, lawyers and certified public accountants, many of whom have previously worked at some of the world’s largest and most prestigious financial institutions. Deltec specializes in providing its clients with private banking and fiduciary expertise, fund administration, investment management solutions, digital asset financial services, insurance, and corporate and merchant banking capabilities.

Following the purchase of Société Generale’s private banking business in The Bahamas in 2016, Deltec has seen its group-wide assets under management, administration and custody rise to over $12 billion, as of late 2019 (http://nnw.fm/n0YQx).

Deltec Bank has received a number of accolades throughout its lengthy history, most recently being named the ‘Best Private Bank in the Caribbean 2020’ by Global Banking and Finance Review (http://nnw.fm/jx4rS), an award which it also won in 2015. The company was recognized for its outstanding performance and achievements, scoring particularly highly in the following categories:

  • Strong client relations with personal and client-focused services;
  • Highly personalized and innovative products and services; and
  • Continued commitment to providing clients with the best possible financial solutions.

Opportunity within Fintech

Remarkably for a private bank, Deltec Bank & Trust has historically been at the forefront of the digital banking and fintech revolution within the financial services industry. Deltec has also gained renown for its annual conference, with the latest iteration focusing on disruption with financial services (http://nnw.fm/3m0kX). Hosting over 300 delegates, including the Deputy Prime Minister & Minister of Finance of The Bahamas, the conference featured ‘The Innovator’s Marketplace’, a forum providing an opportunity for emerging companies in biotech/life sciences, virtual reality, blockchain, fintech, quantum computing and other cutting-edge industries to pitch their ideas to investors and attendees in 45-minute presentations.

Engagement with the Community

Deltec Bank has long held strong ties within the local community in The Bahamas through its Deltec Initiatives Foundation, which was designed to foster an environment that empowers young Bahamians to drive positive social impact through the power of arts, entrepreneurship and education.

Since 2013, the foundation has discovered, launched and mentored many talented, motivated and driven Bahamian artists, artisans and entrepreneurs. The Deltec Initiatives Foundation comprises three pillars: The Initiative for the Arts, The Initiative for Young Entrepreneurs and The Initiative for Scholarship & Education.

Expert Team of Professionals

Jean Chalopin, chairman of Deltec International Group, is a global business leader with a remarkably diverse background encompassing several industries, including banking, wealth management, biotechnologies and entertainment.

Odetta Morton, CEO of Deltec Bank & Trust, is a seasoned banker and CPA with over 20 years of experience in the financial services sector, including financial management, shareholder relations, business leadership and corporate strategy.

Gregory Pepin, Deputy CEO of Deltec Bank & Trust, is an expert financial strategist with vast experience in blockchain technology, investments, wealth management and insurance.

Fabio Gama, Chief Operating Office of Deltec Bank & Trust, has 15 years’ experience in the financial services industry, Fabio has been directly responsible for operations, IT, facilities and procurement. He is an expert in developing teams and has a proven track record for supporting business needs.

Tanya Carey, Chief Financial Officer of Deltec Bank & Trust, is a resourceful finance professional and licensed CPA with over 20 years of experience in financial services and solid industry and regulatory knowledge.

Terry Girling, Chief Administrative Officer of Deltec Bank & Trust, is a senior executive, chartered accountant and banking professional with over 40 years of experience in the finance and banking sectors. Girling is experienced in all facets of banking, including accounting, compliance, operations, technology, fund administration, trust administration and human resources.

Hugo Rogers, Chief Investment Officer of Deltec Bank & Trust, is a multi-asset investment and award-winning global equity and hedge fund manager. He has actively managed investments for over 15 years. He is also a CFA Charterholder with a master’s degree from Oxford University.


Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.